Form 4: Sarepta Therapeutics Executive Bilal Arif Reports Stock Sales Following PSU Vesting

Chief Tech Ops Officer Bilal Arif reports the vesting of performance stock units (PSUs) and subsequent stock sales to cover tax obligations and under a pre-arranged trading plan.

Summary

• Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, reported the vesting of 6,250 performance stock units (PSUs) on June 21, 2024.
• These PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of a prescribed milestone.
• Following the vesting, 2,352 shares were sold by the company to satisfy tax withholding obligations.
• Arif also sold a total of 7,859 shares between June 24 and June 25, 2024, at prices ranging from $162.31 to $167.13 per share, under a Rule 10b5-1 trading plan adopted on March 11, 2024.
• After these transactions, Arif directly owns 17,363 shares of Sarepta Therapeutics common stock and 6,250 Performance Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine executive compensation and stock sales under a pre-arranged plan. The vesting of PSUs suggests achievement of performance milestones, which is mildly positive.

Positives

• The vesting of PSUs indicates the company achieved a performance milestone as determined by the Compensation Committee.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects. Rule 10b5-1 plans are often used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PSUs to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in compliance with insider trading regulations.
• Comparing Arif's transactions to those of executives at similar biotech companies (e.g., BioMarin, Vertex) would provide context on the scale and frequency of such activities.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but the pre-arranged trading plan mitigates concerns about insider trading.
• The vesting of PSUs reflects the company's performance, which is a positive signal for shareholders.

Key Dates